carbamates has been researched along with Thrombopenia in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (66.67) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 2 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Katsuyama, H | 1 |
| Hiraishi, C | 1 |
| Hakoshima, Y | 1 |
| Yanai, H | 1 |
| Forns, X | 1 |
| Poordad, F | 1 |
| Pedrosa, M | 1 |
| Berenguer, M | 1 |
| Wedemeyer, H | 1 |
| Ferenci, P | 1 |
| Shiffman, ML | 1 |
| Fried, MW | 1 |
| Lovell, S | 1 |
| Trinh, R | 1 |
| Lopez-Talavera, JC | 1 |
| Everson, G | 1 |
| Kunschner, LJ | 1 |
| Fine, H | 1 |
| Hess, K | 1 |
| Jaeckle, K | 1 |
| Kyritsis, AP | 1 |
| Yung, WK | 1 |
| REVOL, L | 1 |
| BOTHIER, F | 1 |
| THOUVEREZ, JP | 1 |
| CROIZAT, P | 1 |
| VELASCO, HA | 1 |
| ROSS, CA | 1 |
| WEBSTER, JH | 1 |
| SOKAL, JE | 1 |
| STUTZMAN, L | 1 |
| AMBRUS, JL | 1 |
| Rowinsky, EK | 1 |
| Long, GS | 1 |
| Noe, DA | 1 |
| Grochow, LB | 1 |
| Bowling, MK | 1 |
| Sartorius, SE | 1 |
| Donehower, RC | 1 |
| Elias, EG | 1 |
| Band, PR | 1 |
| Mittelman, A | 1 |
| Colsky, J | 1 |
| Regelson, W | 1 |
| Shnider, BI | 1 |
| Hanley, JA | 1 |
| Pratt, CB | 1 |
| Wang, JJ | 1 |
| Gailani, S | 1 |
| Blais, M | 1 |
| Luce, JK | 1 |
| Bodey, GP | 1 |
| Karpenko, VN | 1 |
| Bross, ID | 1 |
| Rimm, AA | 1 |
| Slack, NH | 1 |
| Ausman, RK | 1 |
| Jones, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered With Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (TURQUOIS[NCT01704755] | Phase 3 | 381 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Virologic failure during treatment was defined as rebound (confirmed HCV RNA greater than or equal to the lower limit of quantitation [≥ LLOQ] after HCV RNA < LLOQ during treatment, or confirmed increase from the lowest value post baseline in HCV RNA [2 consecutive HCV RNA measurements > 1 log(subscript)10(subscript) IU/mL above the lowest value post baseline] at any time point during treatment), or fail to suppress (HCV RNA ≥ LLOQ persistently during treatment with at least 6 weeks [≥ 36 days] of treatment). (NCT01704755)
Timeframe: Baseline (Day 1), and Treatment Weeks 1, 2, 4, 6, 8, 10, 12, 16, 20, and 24
| Intervention | Percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks | 0.5 |
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks | 1.7 |
The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [< LLOQ]) 12 weeks after the last dose of study drug. (NCT01704755)
Timeframe: 12 weeks after the last actual dose of study drug
| Intervention | Percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks | 91.8 |
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks | 96.5 |
A sustained virologic response is defined as plasma Hepatitis C virus ribonucleic acid (HCV RNA) less than the lower limit of quantification (< LLOQ) 12 weeks after the last dose of study drug. (NCT01704755)
Timeframe: 12 weeks after the last actual dose of study drug
| Intervention | Percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks | 91.8 |
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks | 96.5 |
Participants were considered to have virologic relapse after treatment if they had confirmed quantifiable plasma Hepatitis C virus ribonucleic acid (HCV RNA) ≥ lower limit of quantification (LLOQ) between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA < LLOQ at the end of treatment. (NCT01704755)
Timeframe: within 12 weeks after the last dose of study drug
| Intervention | Percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks | 5.9 |
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks | 0.6 |
6 trials available for carbamates and Thrombopenia
| Article | Year |
|---|---|
Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Dru | 2015 |
CI-980 for the treatment of recurrent or progressive malignant gliomas: national central nervous system consortium phase I-II evaluation of CI-980.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carbamates; Disease-Free Survival; Female; Glio | 2002 |
Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent.
Topics: Adult; Aged; Antineoplastic Agents; Carbamates; Central Nervous System Diseases; Dose-Response Relat | 1997 |
Clinical evaluation of two weekly dose schedules of 'IC-140'. 4-N, N-bis (2-Chloroethyl) amino phenyl N (P-carboxyphenyl) carbamate, in the treatmentment of solid tumors 1,2.
Topics: Adenocarcinoma; Breast Neoplasms; Carbamates; Clinical Trials as Topic; Drug Administration Schedule | 1975 |
Clinical trial of acetylenic carbamate: 1,1-diphenyl-2-propynyl cyclohexanecarbamate (NSC-112682).
Topics: Adolescent; Adult; Aged; Alkynes; Antineoplastic Agents; Carbamates; Carcinoma, Bronchogenic; Carcin | 1970 |
Initial clinical trials with 1,1-diphenyl-2-propynyl cyclohexanecarbamate (NCS-112682).
Topics: Alkynes; Antineoplastic Agents; Bone Marrow; Carbamates; Clinical Trials as Topic; Cyclohexanes; Eva | 1970 |
6 other studies available for carbamates and Thrombopenia
| Article | Year |
|---|---|
Severe thrombocytopenia due to repaglinide in a patient with type 2 diabetes.
Topics: Aged; Carbamates; Diabetes Mellitus, Type 2; Humans; Male; Piperidines; Thrombocytopenia | 2013 |
[A CASE OF ALLERGIC THROMBOPENIA DUE TO PROPINYL-2-CYCLOHEXANOL CARBAMATE].
Topics: Carbamates; Cyclohexanols; Drug Hypersensitivity; Humans; Hypnotics and Sedatives; Purpura; Purpura, | 1963 |
COMBINED USE OF AB-132 (METUREDEPA, TURLOC) AND X-IRRADIATION IN THE MANAGEMENT OF ADVANCED BRONCHOGENIC CARCINOMA.
Topics: Alkylating Agents; Antineoplastic Agents; Aziridines; Biomedical Research; Carbamates; Carcinoma, Br | 1964 |
Acetylenic carbamate in childhood cancer.
Topics: Acute Disease; Adolescent; Age Factors; Alkynes; Blood Cell Count; Bone Neoplasms; Carbamates; Child | 1971 |
[Hemopoiesis and the blood clotting system in poisoning with different carbamino pesticides].
Topics: Anemia, Aplastic; Animals; Blood Coagulation; Blood Coagulation Disorders; Carbamates; Environmental | 1971 |
Is toxicity really necessary? II. Source and analysis of data.
Topics: Alkylating Agents; Carbamates; Chlorambucil; Fluorouracil; Humans; Leukocyte Count; Leukopenia; Merc | 1966 |